^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PMB-CT01

    i
    Other names: PMB-CT01, BAFF-R CAR-T cells, PMBCT01, PMB CT01
    Associations

    News

    Trials
    Company:
    PeproMene Bio
    Drug class:
    BAFF-R-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    9ms
    BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL (clinicaltrials.gov)
    P1, N=24, Recruiting, PeproMene Bio, Inc. | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    TNFRSF13C expression
    |
    PMB-CT01
    1year
    Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study (ASH 2023)
    The lymphodepletion regimen consists of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day for 3 days...All CRS events resolved with 2 doses of tocilizumab given to patient #1 and 1 dose to patient #2... PMB-CT01(BAFFRCAR T cell) treatment at DL1 was safe and demonstrated potent anti-lymphoma activity with a 100% ORR (2 CR, 1 PR) in patients with poor prognosis. CRS and ICANS were all grade 1 and reversible. Enrollment is ongoing at DL2, and additional clinical and correlative analyses will be presented at the meeting.
    Clinical • P1 data • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD19 expression • TNFRSF13C expression
    |
    cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • PMB-CT01
    1year
    PMB-BAFFR-102: BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL (clinicaltrials.gov)
    P1; N=18 --> 36 | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jul 2025 --> Jul 2027
    CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement • CD20 negative • TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    almost2years
    BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL (clinicaltrials.gov)
    P1; Trial completion date: Apr 2025 --> Nov 2026 | Trial primary completion date: Apr 2024 --> Nov 2025
    CAR T-Cell Therapy • Trial completion date • Trial primary completion date
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    2years
    BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL (clinicaltrials.gov)
    P1; N=37 --> 24 | Trial completion date: Apr 2024 --> Apr 2025
    CAR T-Cell Therapy • Trial completion date • Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    2years
    PMB-BAFFR-102: BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory MCL (clinicaltrials.gov)
    P1; Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jul 2025
    CAR T-Cell Therapy • Trial completion date • Trial primary completion date
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    over2years
    PMB-BAFFR-102: BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory MCL (clinicaltrials.gov)
    P1; Not yet recruiting --> Recruiting
    CAR T-Cell Therapy • Enrollment open
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    over2years
    BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory MCL (clinicaltrials.gov)
    P1; N=18; Not yet recruiting; Sponsor:PeproMene Bio, Inc.
    CAR T-Cell Therapy • New P1 trial
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    almost3years
    Leukemia-Specific Immune Cells (BAFFR- CAR T Cells) for the Treatment of Relapsed or Refractory B-cell ALL (clinicaltrials.gov)
    P1; Active, not recruiting --> Recruiting | N=21 --> 37
    CAR T-Cell Therapy • Enrollment change • Enrollment open • Clinical
    |
    CD19 (CD19 Molecule)
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    3years
    Leukemia-Specific Immune Cells (BAFFR- CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1; Suspended --> Active, not recruiting
    CAR T-Cell Therapy • Enrollment closed • Clinical
    |
    CD19 (CD19 Molecule)
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    over3years
    Leukemia-Specific Immune Cells (BAFFR- CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1; Recruiting --> Suspended
    CAR T-Cell Therapy • Trial suspension • Clinical
    |
    CD19 (CD19 Molecule)
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    over3years
    Leukemia-Specific Immune Cells (BAFFR- CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1; Trial completion date: Jan 2024 --> Apr 2024 | Initiation date: Jan 2021 --> Apr 2021 | Trial primary completion date: Jan 2024 --> Apr 2024
    Trial completion date • Trial primary completion date • Trial initiation date • Clinical
    |
    CD19 (CD19 Molecule)
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    almost4years
    Leukemia-Specific Immune Cells (BAFFR- CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=21, Recruiting, PeproMene Bio, Inc.
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    PMB-CT01